计算溶液所需的质量、体积或浓度。
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
DSR-141562 is a novel, orally active, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC 50 of 43.9 nM, and the IC 50 values for human PDE1A and 1C are 97.6 and 431.8 nM, respectively. DSR-141562 can be used for the study of positive symptoms, negative symptoms and cognitive impairments associated with schizophrenia
In Vivo
DSR-141562 (oral administration; 30 mg/kg; single dose; plasma and brain exposures 0.5, 1, 2, and 3 hours after administration) exhibits good brain uptake, with the brain-to-blood concentration ratio of unbound drug being 0.99 in rats. DSR-141562 (oral administration; 10 mg/kg; single dose; 2 hours) slightly but significantly increases cGMP contents in the frontal cortex and striatum in rat . DSR-141562 (oral administration; 30 mg/kg or 100 mg/kg; single dose; 2 hours) causes a significant increase in cGMP concentration in monkey CSF. The plasma concentrations of unbound this compound are above 43.9 nM (IC50s)for PDE1B in vitro (43.9 nM). DSR-141562 causes a significant increase in cGMP concentration in monkey CSF . DSR-141562 (oral administration; 3 mg/kg, 10 mg/kg and 30 mg/kg; single dose) significantly reverses methamphetamine-induced locomotor hyperactivity, but has no effect on spontaneouslocomotor activity at 3 and 10 mg/kg . DSR-141562 (oral administration; 0.3 mg/kg, 1 mg/kg or 3 mg/kg) significantly reversed the phencyclidine-induced decrease of social interaction time in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male SpragueDawley rats Dosage: 3 mg/kg, 10 mg/kg and 30 mg/kg Administration: Oral administration; single dose Result: Inhibited methamphetamine-induced locomotor hyperactivity in rats, while it had only minimal effects on the spontaneous locomotor activity. Animal Model: Male SpragueDawley rats Dosage: 0.3 mg/kg, 1 mg/kg or 3 mg/kg Administration: Oral administration; single dose Result: Reversed social interaction.
Form:Solid
IC50& Target:IC50: 43.9 nM (human PDE1B) IC50: 97.6 nM (human PDE1A) IC50: 431.8 nM (human PDE1C)
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机氧化合物 |
| 类(Class) | 有机氧化合物 |
| 亚类(Subclass) | 醚 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 烷基芳基醚 |
| 其他上位类(Alternative Parents) | 氧烷 1,2,4-三嗪 杂芳族化合物 唑类 内酰胺类 氧环化合物 二烷基醚 氮杂环化合物 有机光子化合物 有机氮化合物 有机氟化物 有机氧化物 碳氢化合物衍生物 烷基氟化物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 1,2,4-三嗪 - 芳基醚 - 氟化烷基 - 烷基溴化物 - 芳香族杂多环化合物 - 氮杂环 - 吡唑 - 二烷基醚 - 杂芳香族化合物 - 烃衍生物 - 肟 - 有机硝基化合物 - 有机氧化物 - 有机氟化物 - 有机卤化物 - 有机杂环化合物 - 有机氮化合物 - 有机氮化合物 - 氧杂环 - 氧杂环丁烷 - 三嗪 |
| 描述(Description) | 该化合物属于有机化合物中的烷基芳基醚类。这类化合物含有烷基芳基醚官能团,通式为R-O-R',其中R为烷基,R'为芳基。 |
| 外部描述符(External Descriptors) | 暂无 |